other material
confidence high
sentiment neutral
materiality 0.60
Kyverna Therapeutics enters into $50M at-the-market equity offering facility with Jefferies
Kyverna Therapeutics, Inc.
- Agreement with Jefferies LLC allows sale of up to $50M of common stock from time to time.
- Agent compensation set at 3.0% of gross sales price per share sold.
- Company has no obligation to sell any shares under the Sales Agreement.
- Sales will be made under Company's existing shelf registration statement (Form S-3) filed same day.